Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics ofASKG915 as a Single Agent in Patients with Selected Advanced Solid Tumors
Contact:
NCT Number:
Protocol:
AAAU6331
Study Status:
Closed to Accrual, Study Active
Population:
Adult
Phase:
I
The purpose of this study is to test the safety and effectiveness of ASKG915 at different dose levels to find out what effects, good or bad, this study drug has on you and your cancer. ASKG915 is an experimental treatment that is being developed for treating people with advanced solid tumors. “Experimental” means the study drug has not been approved for the treatment of participants with cancer by the Food and Drug Administration (“FDA”) or any other health/regulatory authority anywhere in the world. This is the first time ASKG915 is being tested in humans.
Are you Eligible? (Inclusion Criteria)
- You are 18 years of age or older 2. You have a life expectancy of ≥ 3 months 3. You have not received any other investigational drug for treatment that is not commercially available within 4 weeks prior to the start of the study treatment. 4. You have not had a prior major organ surgery
Specialty Area(s)
Bladder Cancer , Esophageal Cancer, Gynecologic Cancers, Cervical Cancer, Ovarian Cancer, Head and Neck/Oral Cancers, Lung cancer, Testicular Cancer
Principal Investigator
Trial Location(s)
CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032
